Itraconazole for the treatment of onychomycosis

International Journal of Dermatology

Volumn 37, Issue 4, 1998, Pages 303-308

  Gupta, Aditya K ^a,h   De Doncker, Piet ^b   Scher, Richard K ^c   Haneke, Eckart ^d   Daniel, C Ralph ^e   André, Josette ^f   Baran, Robert ^g  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

^c College of Physicians and Surgeons ^*  (United States)

^d UNIVERSITY OF WITTEN HERDECKE   (Germany)

^e UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^f SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^g NAIL DISEASE CENTRE   (France)

^h NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ITRACONAZOLE; MICONAZOLE; PLACEBO;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CLINICAL TRIAL; DERMATOPHYTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; FATIGUE; FINGER NAIL; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; ONYCHOMYCOSIS; PHARMACODYNAMICS; PRURITUS; TOE; VERTIGO;

ANTIFUNGAL AGENTS; DERMATOMYCOSES; HUMANS; ITRACONAZOLE; ONYCHOMYCOSIS; TREATMENT OUTCOME;

EID: 0031970289     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.1998.00360.x     Document Type: Article

References (41)

1. Hay RJ. Onychomycosis: agents of choice. Dermatol Clin 1993; il: 161-169.
2. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994; 30: 911-933.
3. Gupta AK, Scher RK, De Doncker P. Current management of onychomycosis: an overview. Dermatol Clin 1997; 15: 121-135.
4. Lesher JL. New antifungal agents. Dermatol Clin 1992; 10: 799-805.
5. Roseeuw D, De Doncker P. New approaches to the treatment of onychomycosis. J Am Acad Dermatol 1993; 29: 845-550.
6. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part I. J Am Acad Dermatol 1994; 30: 377396.
7. Hay RJ. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol 1993; 29: 550-854.
8. Van Doorslaer E, Tormans G, Gupta AK, et al. Costeffectiveness comparison of itraconazole continuous dosing, itraconazole pulse, terbinafine, and ciclopirox for the treatment of pedal onychomycosis. Dermatology 1996; 193: 239-244.
9. Espinel-Ingroff A, Shadomy S, Gebhart RJ. In vitro studies with R 51,211 (itraconazole). Antimicrob Agents Chemother 1984; 2.6: 5-9.
10. Cauwenbergh G, Degreef H, Heykants J, et al. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988; 18: ±63-268.
11. Matthieu L, De Doncker P, Cauwenbergh G, et al. Itraconazole penetrates the nail via the nail matrix and the nail bed - an investigation in onychomycosis. Clin Exp Dermatol 1991; 16: 374-376.
12. Willemsen M, De Doncker P, Willems J, et al. Posttreatment itraconazole levels in the nail. J Am 'Acad Dermatol 1992; 26: 731-735.
13. De Doncker P, Van Lint J, Dockx P, et al. Pulse therapy with one-week itraconazole monthly for three or four months in the treatment of onychomycosis. Cutis 1995; 56: 180-183.
14. De Doncker P, Decroix J, Pierard GE, et al. Antifungal pulse therapy for onychomycosis. Arch Derinatol 1996; 132: 34-41.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986; 7: 177-188.
16. Velanovich V. Meta-analysis for combining Bayesian probabilities. Med Hypoth 1991; 35: 191-195.
17. Montoya De Bayona LS, Rincon Stella M, Ramirez Quintero G. Itraconazole in the treatment of onychomycosis. Revista de la Universidad Industrial de Santander - Medicina 1987; 15: 141-152..
18. Walsoe I, Stangerup M, Svejgaard E: Itraconazole in onychomycosis. Acta Derinatol Venereal (Stockh) 1990; 70: 137-140-
19. Hay RJ. Itraconazole 100 mg capsules for onychomycosis. Janssen Expert Report N 9532.5/1, 1993: 1-106.
20. Cabrai F, Couto J, Velho R. Itraconazole in the treatment of onychomycoses. Trab Soc Port Derm Ven 1988; XLVI: 157-160.
21. Hay RJ, Clayton YM, Moore MK, et al. An evaluation of itraconazole in the management of onychomycosis. Er J Dermatol 1988; 119: 359-366.
22. Pieponen T, Blomqvist K, Brandt H, et al. Efficacy and safety of itraconazole in the long-term treatment of onychomycosis. J Antimicrob Chetnother 1992.; 29: 195-205.
23. Rongioletti F, Robert E, Tripodi S, et al. Treatment of onychomycosis with itraconazole. ] Dermatol Treat 1992; 2: 145-146.
24. Arenas R, Fernandez G, Dominguez L. Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent. Int J Dermatol 1991; 30: 586-589.
25. Kagawa S. A clinical evaluation of itraconazole, a new oral antifungal agent, in the treatment of tinea unguium, Candida onychomycosis and Candida onychia/ paronychia. The Clinical Report 1991; 25: 433-448.
26. Heremans A, Aerts T, Hucke H, et al. Overview of efficacy and safety of itraconazole in the treatment of onychomycosis. Janssen Clinical Research Report N 95166/1, 1993: 1-148.
27. Haneke E, Delescluse J, Plinck EPB, et al. The use of itraconazole in onychomycosis. Eur J Dermatol 1996; 6: 7-io.
28. De Doncker P. Challenges in treatment. Itraconazole for the management of onychomycosis. Second International Symposium on Onychomycosis. Florence, Italy, September 1995.
29. André J, De Doncker P, Ginter G, et al. Intermittent pulse therapy with itraconazole in onychomycosis: an update. Poster presented at the American Academy of Dermatology 5ist Annual Meeting, Washington, DC, February 1996.
30. Heremans A. Clinical expert summary on itraconazole for the treatment of onychomycosis with a shortened regime of zoo mg b.i.d. X 7 days/month for z or 3 months. Janssen Clinical Research Report N inözjM, 1995: 1-44.
31. Havu V, Brandt H, Heikkilä H, et al A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. Br J Dennatol 1997; 13) 230-134.
32. Hay RJ, Clayton YM, Moore MK, et al. An evaluation of itraconazole in the management of onychomycosis. Br J Dennatol 1988; 119: 359-366.
33. Kim JA, Ahn KJ, Kim JM, et al. Efficacy and tolerability of itraconazole in patients with fingernail onychomycosis: a 6-week pilot study. Curr Ther Res 1995; 56: 1066-1075.
34. Rashid A, De Doncker P. Pulse-dose regimen of oral itraconazole in the treatment of Candida paronychia. Poster presented at the Dermatology zooo meeting, Vancouver, B.C., May, 1996.
35. De Doncker P, Scher RK, Baran RL, et al. Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with molds with dermatophytes: a multicenter study with 36 patients. J Am Acad Dennatol 1997; 36: 173-177.
36. Conant M. Superficial fungal infections in AIDS patients. 5th International Skin Therapy Symposium, Brussels, Belgium, May 1994.
37. Nolting S, Gupta AK, De Prost Y, et al. Itraconazole for the treatment of dermatomycoses in children. Submitted.
38. Gupta AK, Sibbald RG, Lynde CW, et al. A survey and treatment of onychomycosis in children. J Am Acad Dennatol 1997; 36: 395-400.
39. Baran R, De Doncker P. Lateral edge nail involvement indicates poor prognosis for treating onychomycosis with the new systemic antifungals. Acta Derm Venereal (Stockh) 1996; 76: 82-83.
40. Haneke E, Ring J, Tajerbashi D, et al. Efficacy and safety of itraconazole i-week pulse therapy in the treatment of onychomycosis: an open German multicenter trial. Poster presented at the 54th Annual meeting of the American Academy of Dermatology, February 10-15, J996. Washington DC, USA.
41. Intraconazole international product monograph. Beerse, Belgium, 1996.